Heart rate: \< 50 or \> 120, or Respiratory Rate: \< 10 or \> 30.
Altered mental status.
Patient is unwilling to participate or provide informed consent.
Any allergy to ketamine or diphenhydramine.
Patient is female of child-bearing age and unwilling to provide urine or blood for HCG analysis.
Pregnant or breastfeeding.
Presence of intracranial mass or vascular lesion.
Presence of a history of psychosis or hallucinations (as assessed by electronic chart review).
Weight greater than 115 kg or less than 45kg.
History of increased intracranial pressure/hypertensive hydrocephalus or increased intraocular pressure.
Patient is acutely psychotic.
Provider feels that patient currently or likely will require chemical and/or physical restraints.
History of prolonged QT-interval.
Current treatment includes any medication known to affect the N-methyl-D-aspartate receptor system (e.g., lamotrigine, acamprosate, memantine, riluzole, or lithium).
Patient in withdrawal from substance abuse or who have used hallucinogens (including cannabis) in the last month for any indication, as determined by the clinical interview and urine drug screening.
Clareo Health | A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients
